Although the relevance of these non-BRCA gene mutations in the effects PARP inhibitors is not completely clarified, their synchronous presence with ATRX loss raises the possibility that ATRX-deficient high-grade gliomas are promising targets of PARP inhibitors. The gene discussed is ATRX; the disease is central nervous system cancer.